Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Agenus Inc. (NASDAQ: AGEN) provided a corporate update alongside its Q3 2020 financial results. The company initiated its rolling BLA filing for Balstilimab, with FDA review in progress. Recent clinical trials show Balstilimab achieving a 19% response rate in PD-L1 positive tumors and a combination with zalifrelimab yielding 27%. The cash balance rose to $114 million, while Q3 net loss was $52 million, a slight increase from $46 million in Q3 2019. Revenues totaled $14.8 million, down from $19.9 million in the prior year. New data on AGEN1181 will be presented at the upcoming SITC meeting.
Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020. A conference call and webcast will follow at 8:30 AM ET for a discussion of the results and corporate update. Agenus specializes in immuno-oncology with an extensive pipeline including checkpoint antibodies, cell therapies, and vaccines aimed at enhancing immune responses to cancer and infections. The call will be accessible via the company’s website.
Agenus Inc. (NASDAQ: AGEN) announced the acceptance of seven abstracts for the virtual SITC 2020 Annual Meeting, scheduled for November 9-14, 2020. Key presentations include:
- AGEN1181: Demonstrates clinical activity as a standalone or in combination with balstilimab.
- Zalifrelimab: Shows clinical benefit in rare tumors.
- AGEN2373: A CD137 agonist antibody targeting antitumor effects.
- AgenT-797: A novel cell therapy promoting tumor killing.
Updated data will be available on the Agenus website post-conference.
Agenus Inc. (NASDAQ: AGEN) announced the election of Susan Hirsch to its Board of Directors, a significant move as the company prepares for its initial commercial product launches. Garo Armen, Chairman and CEO, praised Hirsch's extensive experience, particularly in identifying high-value companies at critical growth stages. With over 40 years in investment management, including a leadership role at Nuveen, Hirsch's expertise is expected to enhance Agenus' strategic direction. The company is focused on developing therapies that engage the immune system to combat cancer.
Agenus Inc. (NASDAQ: AGEN) announced the initiation of the rolling submission of its Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, to the FDA for treating recurrent/metastatic cervical cancer. Results from a significant phase 2 trial indicated response rates of 19% in PD-L1 positive patients and 14% overall. The rolling BLA submission allows for concurrent FDA review of each section as it is completed. The American Cancer Society reported around 14,000 new cervical cancer cases expected this year, highlighting the need for new therapies.
Agenus Inc. (NASDAQ: AGEN) reported preliminary results from two Phase 2 clinical trials at the ESMO Virtual Congress 2020, focusing on recurrent/metastatic cervical cancer. The balstilimab monotherapy trial showed a 14% response rate overall and 19% in PD-L1 positive patients. The combination of balstilimab and zalifrelimab achieved a 22% overall response rate and 27% in PD-L1 positive patients. Notably, the median duration of response was 15.4 months for balstilimab alone. Both therapies show potential as new options for patients with limited treatment choices.
Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, participated in a fireside chat series with Scientific American on September 16, 2020. Dr. Buell discussed Agenus’ immunotherapy innovations in combating COVID-19, emphasizing the significance of combination therapies and improving patient access. The replay of the event is accessible online. Agenus, a clinical-stage immuno-oncology company, aims to enhance patient outcomes through a variety of therapeutic approaches, including antibody therapeutics and cancer vaccine platforms.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company, will host a webcast on September 21, 2020, at 2:30 p.m. ET featuring Dr. David O’Malley, who will discuss the data on balstilimab and zalifrelimab presented at ESMO. The session will cover the largest clinical trials concerning refractory cervical cancer and the future of this proprietary combination therapy. Additional discussions will involve progress on Agenus' pipeline assets, including AGEN1181 and various TIGIT therapies. A replay will be available on Agenus’ website.
Agenus Inc. (NASDAQ: AGEN) announced the election of Paul Clark to its Board of Directors on August 31, 2020. Clark brings over 30 years of experience in the pharmaceutical and biotech industries, including leadership roles at ICOS and Abbott Laboratories. His expertise is expected to aid Agenus in transitioning to a commercial company as it prepares for the launch of its first immuno-oncology antibodies. Chairman and CEO Garo Armen highlighted Clark's valuable insights, anticipating positive impacts from his extensive experience in product development and commercialization.
Agenus Inc. (NASDAQ: AGEN) announced that data from two Phase 2 trials of balstilimab, both alone and in combination with zalifrelimab, will be presented at the European Society of Medical Oncology (ESMO) Conference on September 18, 2020. Dr. David O'Malley from Ohio State University will present the findings. The company remains on track to initiate a rolling Biologics License Application (BLA) submission for balstilimab monotherapy this quarter and aims to complete a data packet for the combination therapy by year-end.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
